ATE275967T1 - Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie - Google Patents

Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie

Info

Publication number
ATE275967T1
ATE275967T1 AT01900978T AT01900978T ATE275967T1 AT E275967 T1 ATE275967 T1 AT E275967T1 AT 01900978 T AT01900978 T AT 01900978T AT 01900978 T AT01900978 T AT 01900978T AT E275967 T1 ATE275967 T1 AT E275967T1
Authority
AT
Austria
Prior art keywords
exendins
hypertriglyceridemia
agonists
treatment
exendin
Prior art date
Application number
AT01900978T
Other languages
German (de)
English (en)
Inventor
Orville Gene Kolterman
Andrew A Young
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22639978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE275967(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE275967T1 publication Critical patent/ATE275967T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01900978T 2000-01-10 2001-01-09 Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie ATE275967T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17536500P 2000-01-10 2000-01-10
PCT/US2001/000719 WO2001051078A1 (en) 2000-01-10 2001-01-09 Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia

Publications (1)

Publication Number Publication Date
ATE275967T1 true ATE275967T1 (de) 2004-10-15

Family

ID=22639978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01900978T ATE275967T1 (de) 2000-01-10 2001-01-09 Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie

Country Status (11)

Country Link
US (1) US20030036504A1 (cg-RX-API-DMAC7.html)
EP (1) EP1246638B2 (cg-RX-API-DMAC7.html)
JP (1) JP2003519667A (cg-RX-API-DMAC7.html)
AT (1) ATE275967T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006202247A1 (cg-RX-API-DMAC7.html)
CA (1) CA2396157A1 (cg-RX-API-DMAC7.html)
DE (1) DE60105547T3 (cg-RX-API-DMAC7.html)
DK (1) DK1246638T4 (cg-RX-API-DMAC7.html)
ES (1) ES2227115T5 (cg-RX-API-DMAC7.html)
PT (1) PT1246638E (cg-RX-API-DMAC7.html)
WO (1) WO2001051078A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
CA2277112C (en) * 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
EP1634605A3 (en) * 2000-03-08 2006-10-11 Novo Nordisk A/S treatment of dyslipidemia in a patient having type 2 diabetes
EP2022505B1 (en) 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
ATE419863T1 (de) 2001-09-24 2009-01-15 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
EP2335715A3 (en) 2004-02-11 2013-12-18 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1853627A2 (en) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US20060190425A1 (en) * 2005-02-24 2006-08-24 Yuan-Chi Chang Method for merging multiple ranked lists with bounded memory
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US7452868B2 (en) * 2005-03-11 2008-11-18 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
AU2006265814B2 (en) 2005-06-30 2012-05-10 Ipsen Pharma S.A.S. GLP-1 pharmaceutical compositions
EP1922336B1 (en) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
JP2009504681A (ja) * 2005-08-11 2009-02-05 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
PT3524261T (pt) 2005-08-19 2024-01-12 Amylin Pharmaceuticals Llc Exendina para o tratamento da diabetes e redução do peso corporal
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
WO2009039992A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
AU2008297529A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
ES2552646T3 (es) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendinas para disminuir el colesterol y los triglicéridos
JP5622725B2 (ja) * 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
AU2009262263B2 (en) * 2008-06-25 2014-08-14 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
US20120231022A1 (en) 2009-05-28 2012-09-13 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
EP2588490B1 (en) 2010-07-02 2017-02-22 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US9161953B2 (en) 2010-12-22 2015-10-20 Amylin Pharmaceuticals, Llc GLP-1 receptor agonists for islet cell transplantation
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RS57531B1 (sr) 2012-12-21 2018-10-31 Sanofi Sa Derivati eksendina-4 kao dualni glp1/gip- ili trigonalni glp1/gip/glukagon agonisti
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
WO2018071528A1 (en) * 2016-10-11 2018-04-19 University Of Georgia Research Foundation, Inc. Proteins and method for treating obesity and associated comorbidities
EP3551202B1 (en) 2016-12-06 2024-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
MX2019007584A (es) * 2016-12-22 2019-09-04 Sanofi Sa Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada.
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
KR20200019122A (ko) 2017-06-20 2020-02-21 암젠 인크 Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
CA3066251A1 (en) 2017-06-21 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
WO2020185533A1 (en) 2019-03-08 2020-09-17 Amgen Inc. Growth differentiation factor 15 combination therapy
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
CA2277112C (en) * 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
JP2003524582A (ja) * 1997-12-12 2003-08-19 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗高脂血症性スタチン−Ｌｐ（ａ）阻害剤配合物
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
CN1372570A (zh) * 1999-04-30 2002-10-02 安米林药品公司 修饰的exendin和exendin激动剂

Also Published As

Publication number Publication date
PT1246638E (pt) 2004-12-31
EP1246638B2 (en) 2014-07-30
HK1050477A1 (en) 2003-06-27
AU2006202247A1 (en) 2006-06-22
ES2227115T5 (es) 2014-10-30
EP1246638A1 (en) 2002-10-09
DK1246638T4 (da) 2014-09-22
WO2001051078A1 (en) 2001-07-19
AU784488B2 (en) 2006-04-13
DE60105547T3 (de) 2014-12-31
DK1246638T3 (da) 2005-01-10
AU2638001A (en) 2001-07-24
JP2003519667A (ja) 2003-06-24
CA2396157A1 (en) 2001-07-19
EP1246638B1 (en) 2004-09-15
DE60105547T2 (de) 2005-10-13
ES2227115T3 (es) 2005-04-01
DE60105547D1 (de) 2004-10-21
US20030036504A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
ATE275967T1 (de) Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
ATE367169T1 (de) Verwendung von exendins und deren agonisten zur behandlung von schwangerschaftsdiabetes
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
DE602005019856D1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
MX337422B (es) Composiciones y metodos para incrementar la sencibilidad a la insulina.
GB0213612D0 (en) Organic compounds
AR028512A1 (es) Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas
ATE514418T1 (de) Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
DK1343492T3 (da) Behandling af mucositis
MA30768B1 (fr) Methodes d'administration d'agents hypoglycemiques a longue duree d'action
BRPI0414277A (pt) métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
DK1349856T3 (da) Isoindolin-1-on-glucokinase-aktivatorer
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
AR058892A1 (es) Metodos para tratar lupus cutaneo con el uso de compuestos de aminoisoindolina
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
NZ597419A (en) Formulations for the treatment of deep tissue pain
PT1185253E (pt) Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac
MX2008002598A (es) Metodos para aplicar formulaciones antimicrobianas en alimento.
EA200701751A1 (ru) Улучшенные составы фенофибрата
WO2004052294A3 (en) Compositions and methods related to lipid:emodin formulations
DE69934689D1 (de) Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen
AR040737A1 (es) Administracion oral de calcitonina
CL2009000986A1 (es) Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1246638

Country of ref document: EP